Cellectar Biosciences to Present at the 36th Annual Roth Conference
Cellectar Biosciences, Inc. (CLRB) announces Jim Caruso, the President and CEO, will present at the 36th Annual Roth Conference. The presentation will focus on the company's overview and future prospects in cancer drug development.
03/14/2024 - 08:52 AM
FLORHAM PARK, N.J., March 14, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that Jim Caruso, president and chief executive officer of Cellectar, will present an overview of the company in a fireside chat at the upcoming 36th Annual Roth Conference taking place on March 17 to 19, 2024 in Laguna Niguel, CA. Details of the fireside chat are as follows:
Date: Tuesday, March 19, 2024 Time: 9:00 am Pacific Time / 12:00 pm Eastern Time Webcast: Click HERE
A replay of the presentation will be available on the Events section of the company’s investor relations website.
About Cellectar Biosciences, Inc.
The company’s product pipeline includes lead asset iopofosine I 131, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets.
For more information, please visit www.cellectar.com and www.wmclinicaltrial.com or join the conversation by liking and following us on the company’s social media channels: Twitter , LinkedIn , and Facebook .
Contacts
MEDIA:clacagnina@blissbiohealth.com
INVESTORS:investors@cellectar.com
When will Jim Caruso present an overview of Cellectar Biosciences at the 36th Annual Roth Conference?
Jim Caruso will present on Tuesday, March 19, 2024.
Where is the 36th Annual Roth Conference taking place?
The conference is happening in Laguna Niguel, CA.
What is the focus of Cellectar Biosciences, Inc.?
The company is focused on the discovery, development, and commercialization of drugs for cancer treatment.
Where can a replay of the presentation be found?
A replay will be available on the Events section of the company’s investor relations website.
Cellectar Biosciences Inc
CLRB Rankings
#1026 Ranked by Stock Gains
CLRB Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
Florham Park
About CLRB
cellectar biosciences is developing phospholipid drug conjugates (pdcs) designed to provide cancer targeted delivery of diverse oncologic payloads to a broad range of cancers and cancer stem cells. cellectar's pdc platform is based on the company's proprietary phospholipid ether analogs. these novel small-molecules have demonstrated highly selective uptake and retention in a broad range of cancers. cellectar's pdc pipeline includes product candidates for cancer therapy and cancer diagnostic imaging. the company's lead therapeutic pdc, clr 131, utilizes iodine-131, a cytotoxic radioisotope, as its payload. clr 131 has been designated as an orphan drug by the us fda and is currently being evaluated in a phase 1 clinical study in patients with relapsed or refractory multiple myeloma and a phase 2 clinical study to assess efficacy in a range of b-cell malignancies. the company is also developing proprietary pdcs for targeted delivery of chemotherapeutics and has several preclinical stage p
